Aster DM Quality Care Q2: Revenue Up 19%, PAT Grows 34%

ASTERDM Aster DM Quality Care Limited reported a strong Q2 FY27 performance, with revenue growing 19% and normalised profit after tax increasing 34% year-on-year on a combined, comparable basis. Q2 FY27 Financial Performance: Revenue: ₹2,829 crore, up 19% YoY. Operating EBITDA: ₹678 crore, up 25% YoY. Operating EBITDA Margin: 24%, compared with 22.9% last year. Normalised PAT: ₹281 crore, up 34% YoY. Normalised PAT Margin: 9.9%, compared with 8.8%. ROCE: 23%, improving by 152 basis points. Key operating indicators: Occupancy: Improved to 68% from 65% Medical Value Travel Revenue: Increased 36% YoY. Medical Value Travel Volume: Grew 31% YoY. Emerging Hospitals: Recorded approximately 61% revenue growth. Mature Hospitals: Contributed approximately 73% of hospital revenue in H1 FY27, growing 18% YoY. Growth in High-Value Medical Procedures Robotic Surgeries: Increased approximately 39%. Kidney Transplants: Increased approximately 31%. Joint Replacements: Increased approximately 29%. Growth was led by Neurosciences, Oncology, Orthopaedics and Gastroenterology. Investor Perspective: The improvement in operating EBITDA margin to 24% indicates better operating efficiency. Going forward, investors should monitor occupancy levels, expansion costs, merger synergies, operating margins and the contribution of emerging hospitals. The YoY growth figures above are based on the company's combined, comparable financial presentation. Reported historical financial statements were not restated following the merger. Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice or a recommendation to buy or sell any security. Investors should conduct their own research and consider their risk profile before making any investment decision.